Aqueous and alcoholic extracts of triphala and their active compounds chebulagic acid and chebulinic acid prevented epithelial to mesenchymal transition in retinal pigment epithelial cells, by inhibiting SMAD-3 phosphorylation

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Sivasankar, Shanmuganathan ^a,b   Lavanya, Ramu ^b   Brindha, Pemaiah ^b   Angayarkanni, Narayanasamy ^a  

^a VISION RESEARCH FOUNDATION   (India)

^b SASTRA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA SMOOTH MUSCLE ACTIN; ANTIMITOTIC AGENT; AYURVEDIC DRUG; CHEBULAGIC ACID; CHEBULINIC ACID; GALLIC ACID; GELATINASE A; PLANT MEDICINAL PRODUCT; PROTEIN ZO1; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TRIPHALA; UNCLASSIFIED DRUG; VIMENTIN; WATER; BENZOPYRAN DERIVATIVE; GLUCOSIDE; PLANT EXTRACT; TANNIN;

ADULT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL ASSAY; CELL MIGRATION ASSAY; CELL PROLIFERATION ASSAY; CELL SCRATCH ASSAY; CONTROLLED STUDY; DOWN REGULATION; DRUG DETERMINATION; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; PIGMENT EPITHELIUM; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETINA PIGMENT CELL; UPREGULATION; WESTERN BLOTTING; CELL LINE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; METABOLISM; PHOSPHORYLATION; RETINAL PIGMENT EPITHELIUM;

ANIMALIA;

BENZOPYRANS; CELL LINE; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; GLUCOSIDES; HUMANS; HYDROLYZABLE TANNINS; PHOSPHORYLATION; PLANT EXTRACTS; RETINAL PIGMENT EPITHELIUM; SMAD3 PROTEIN;

EID: 84925584582     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120512     Document Type: Article

References (51)

1. Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol. 1995; 79: 953-60. PMID: 7488586
2. Pastor JC. Proliferative Vitreoretinopathy : An Overview. Surv Ophthalmol. 1998; 43: 3-18. PMID: 9716190
3. Pastor JC, de la Rúa ER, Martín F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002; 21: 127-44. PMID: 11906814
4. Sadaka A, Giuliari G. Proliferative vitreoretinopathy: current and emerging treatments. clincal opthalmology. 2012; 6: 1325-33.
5. Nagasaki H, Shinagawa K, Mochizuki M. Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res. 1998; 17: 77-98. PMID: 9537796
6. Campochiaro P. Pathogenic mechanisms in proliferative vitreoretinopathy. Arch Ophthalmol. 1997; 115: 237. PMID: 9046259
7. Ryan SJ. Traction retinal detachment. XLIX Edward Jackson Memorial Lecture. Am J Ophthalmol. 1993; 115: 1-20. PMID: 8420359
8. Saika S, Yamanaka O, Flanders KC, Okada Y, Miyamoto T, Sumioka T, et al. Epithelial-Mesenchymal Transition as a Therapeutic Target for Prevention of Ocular Tissue Fibrosis. Endocr Metab Immune Disord Drug Targets. 2008; 8: 69-76. PMID: 18393925
9. Kalluri R. EMT: When epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 2009. pp. 1417-1419. doi: 10.1172/JCI39675 PMID: 19487817
10. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003; 112: 1776-84. PMID: 14679171
11. Hinton D, He S, Jin M, Barron E, Ryan S. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye. 2002; 16: 422-8. PMID: 12101449
12. Cui J, Chiu A, Maberley D, Ma P. Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Eye. 2007; 21: 200-8. PMID: 16531976
13. Lee H, O'Meara SJ, O'Brien C, Kane R. The role of gremlin, a BMP antagonist, and epithelial-to-mesenchymal transition in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2007; 48: 4291-9. PMID: 17724219
14. Li H, Wang H, Wang F, Gu Q, Xu X. Snail involves in the transforming growth factor β1-mediated epithelial-mesenchymal transition of retinal pigment epithelial cells. PLoS One. 2011; 6: e23322. doi: 10.1371/journal.pone.0023322 PMID: 21853110
15. Pawar V, Lahorkar P, Anantha Narayana DB. Development of a RP-HPLC Method for Analysis of Triphala Curna and its Applicability to Test Variations in Triphala Curna Preparations. Indian J Pharm Sci. 2009; 71: 382-386. doi: 10.4103/0250-474X.57286 PMID: 20502543
16. Sandhya T, Lathika KM, Pandey BN, Mishra KP. Potential of traditional ayurvedic formulation, Triphala, as a novel anticancer drug. Cancer Lett. 2006; 231: 206-14. doi: 10.1016/j.canlet.2005.01.035 PMID: 15899544
17. Shi Y, Sahu RP, Srivastava SK. Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing apoptosis. BMC Cancer. 2008; 8: 294. doi: 10.1186/1471-2407-8-294 PMID: 18847491
18. Reddy DB, Reddanna P. Chebulagic acid (CA) attenuates LPS-induced inflammation by suppressing NF-kappaB and MAPK activation in RAW 264.7 macrophages. Biochem Biophys Res Commun. 2009; 381: 112-7. doi: 10.1016/j.bbrc.2009.02.022 PMID: 19351605
19. Lu K, Chakroborty D, Sarkar C, Lu T, Xie Z, Liu Z, et al. Triphala and its active constituent chebulinic acid are natural inhibitors of vascular endothelial growth factor-a mediated angiogenesis. PLoS One. 2012; 7: e43934. doi: 10.1371/journal.pone.0043934 PMID: 22937129
20. Baliga MS, Meera S, Mathai B, Rai MP, Pawar V, Palatty PL. Scientific validation of the ethnomedicinal properties of the Ayurvedic drug Triphala: a review. Chin J Integr Med. 2012; 18: 946-54. doi: 10.1007/s11655-012-1299-x PMID: 23239004
21. Rothmeier AS, Ischenko I, Joore J, Garczarczyk D, Fürst R, Bruns CJ, et al. Investigation of the marine compound spongistatin 1 links the inhibition of PKCalpha translocation to nonmitotic effects of tubulin antagonism in angiogenesis. FASEB J. 2009; 23: 1127-37. doi: 10.1096/fj.08-117127 PMID: 19056838
22. Basu C, Thornton B. Real-Time PCR (qPCR) Primer Design Using Free Online Software. Biochem Mol Educ. 2011; 39: 145-154. doi: 10.1002/bmb.20461 PMID: 21445907
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25: 402-8. PMID: 11846609
24. Krishnan G, Chatterjee N. Endocannabinoids alleviate proinflammatory conditions by modulating innate immune response in muller glia during inflammation. Glia. 2012; 60: 1629-45. doi: 10.1002/glia.22380 PMID: 22807196
25. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009. 119. 1429-1437. doi: 10.1172/JCI36183 PMID: 19487819
26. Pedro R, Marano C, Pagan R. Epithelial-Mesenchymal Transition in Proliferative Vitreoretinopathy : Intermediate Filament Protein Expression in Retinal Pigment Epithelial Cells. Invest Ophthalmol Vis Sci. 1999; 40: 2062-2072. PMID: 10440262
27. Bochaton-Piallat ML, Kapetanios AD, Donati G, Redard M, Gabbiani G, Pournaras CJ. TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy. Invest Ophthalmol Vis Sci. 2000; 41: 2336-42. PMID: 10892881
28. Kon CH, Occleston NL, Charteris D, Daniels J, Aylward GW, Khaw PT. A Prospective Study of Matrix Metalloproteinases in Proliferative vitreoretinopthy. Invest Ophthalmol Vis Sci. 1998; 39: 1524-1529. PMID: 9660504
29. Coral K, Angayarkanni N, Madhavan J, Bharathselvi M, Ramakrishnan S, Nandi K, et al. Lysyl oxidase activity in the ocular tissues and the role of LOX in proliferative diabetic retinopathy and rhegmatogenous retinal detachment. Invest Ophthalmol Vis Sci. 2008; 49: 4746-52. doi: 10.1167/iovs.07-1550 PMID: 18566459
30. Symeonidis C, Papakonstantinou E, Souliou E, Karakiulakis G, Dimitrakos SA, Diza E. Correlation of matrix metalloproteinase levels with the grade of proliferative vitreoretinopathy in the subretinal fluid and vitreous during rhegmatogenous retinal detachment. Acta Ophthalmol. 2011; 89: 339-45. doi: 10.1111/j.1755-3768.2009.01701.x PMID: 19764916
31. Eichler W, Friedrichs U, Thies A, Tratz C, Wiedemann P. Modulation of matrix metalloproteinase and TIMP-1 expression by cytokines in human RPE cells. Invest Ophthalmol Vis Sci. 2002; 43: 2767-73. PMID: 12147614
32. Duong T, Erickson C. MMP-2 plays an essential role in producing epithelial-mesenchymal transformations in the avian embryo. Dev Dyn. 2004; 229: 42-53. PMID: 14699576
33. Giebel S, Menicucci G, McGuire P, Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab invest. 2005; 85: 597-607. PMID: 15711567
34. Sumantran VN, Kulkarni AA, Harsulkar A, Wele A, Koppikar SJ, Chandwaskar R, et al. Hyaluronidase and collagenase inhibitory activities of the herbal formulation Triphala guggulu. J Biosci. 2007; 32: 755-61. PMID: 17762148
35. Abraham S, Kumar MS, Sehgal PK, Nitish S, Jayakumar ND. Evaluation of the inhibitory effect of triphala on PMN-type matrix metalloproteinase (MMP-9). J Periodontol. 2005; 76: 497-502. PMID: 15857087
36. Bouayed J, Bohn T. Exogenous antioxidants-Double-edged swords in cellular redox state Health beneficial effects at physiologic doses versus deleterious effects at high doses. Oxid Med Cell Longev. 2010; 3: 228-327. PMID: 20972369
37. Williams RJ, Spencer JPE, Rice-Evans C. Flavonoids: antioxidants or signalling molecules? Free Radic Biol Med. 2004; 36: 838-49. PMID: 15019969
38. Burke JM, Hong J. Fate of E-cadherin in Early RPE Cultures: Transient Accumulation of Truncated Peptides at Nonjunctional Sites. Invest Ophthalmol Vis Sci. 2006; 47: 3635-3643. PMID: 16877438
39. Chen H-C, Zhu Y-T, Chen S-Y, Tseng SC. Wnt signaling induces epithelial-mesenchymal transition with proliferation in ARPE-19 cells upon loss of contact inhibition. Lab. invest. 2012. 92. 676-687. doi: 10.1038/labinvest.2011.201 PMID: 22391957
40. Kumar MS, Kirubanandan S, Sripriya R, Sehgal PK. Triphala promotes healing of infected full-thickness dermal wound. J Surg Res. 2008; 144: 94-101. PMID: 17662304
41. Ermakova S, Choi BY, Choi HS, Kang BS, Bode AM, Dong Z. The intermediate filament protein vimentin is a new target for epigallocatechin gallate. J Biol Chem. 2005; 280: 16882-90. PMID: 15713670
42. Sun X-D, Liu X-E, Huang D-S. Curcumin reverses the epithelial-mesenchymal transition of pancreatic cancer cells by inhibiting the Hedgehog signaling pathway. Oncol Rep. 2013; 29: 2401-7. doi: 10.3892/or.2013.2385 PMID: 23563640
43. Chan C-M, Huang J-H, Chiang H-S, Wu W-B, Lin H-H, Hong J-Y, et al. Effects of (-)-epigallocatechin gallate on RPE cell migration and adhesion. Mol Vis. 2010; 16: 586-95. PMID: 20376327
44. Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, et al. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 1997; 16: 5353-62. PMID: 9311995
45. Moustakas A, Heldin C-H. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007; 98: 1512-20. PMID: 17645776
46. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009; 19: 156-72. doi: 10.1038/cr.2009.5 PMID: 19153598
47. Jinnin M, Ihn H, Tamaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-β1-induced extracellular matrix expression. Mol Pharmacol. 2006; 69: 597-607. PMID: 16288083
48. Saika S, Kono-Saika S, Tanaka T, Yamanaka O, Ohnishi Y, Sato M, et al. Smad3 is required for dedifferentiation of retinal pigment epithelium following retinal detachment in mice. Lab Invest. 2004; 84: 1245-58. PMID: 15273699
49. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol. 2004; 85: 47-64. PMID: 15154911
50. Burke JM. Epithelial phenotype and the RPE: is the answer blowing in the Wnt? Prog Retin Eye Res. 2008; 27: 579-95. doi: 10.1016/j.preteyeres.2008.08.002 PMID: 18775790
51. Kim J, Hwan Kim S. CK2 Inhibitor CX-4945 Blocks TGF-β1-Induced Epithelial-to-Mesenchymal Transition in A549 Human Lung Adenocarcinoma Cells. PLoS One. 2013; 8: e74342. doi: 10.1371/journal.pone.0074342 PMID: 24023938